[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-recovery-duo-zh":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":7,"cat":9,"icon":10,"accent":11,"date":12,"dateLabel":13,"updated":14,"read":15,"author":16,"image":17,"faq":18,"body":28,"_type":244,"_id":245,"_source":246,"_file":247,"_stem":248,"_extension":249},"\u002Fblog\u002Fzh\u002Frecovery-duo","zh",false,"","BPC-157 与 TB-500：它们是什么，处于什么状态","化合物","tabler:file-description","#4CAF50","2026-06-05","2026年6月5日","2026-09-04","3 分钟阅读","myPeptides Team","\u002Fassets\u002Fbpc157_tb500_status_hero.png",[19,22,25],{"q":20,"a":21},"BPC-157 和 TB-500 是什么？","BPC-157 是一种由 15 个氨基酸构成的人工合成肽，序列取自胃液中发现的一段结构；TB-500 是胸腺素 β4 的人工合成片段。两者都不是获批药物。",{"q":23,"a":24},"BPC-157 和 TB-500 在体育运动中被禁用吗？","两者在任何时候都被禁用，不只是在赛内。BPC-157 归入 S0，也就是收纳「尚无任何人用治疗用途监管批准」之物质的那一类，2026 年版清单在该类的举例中点了它的名；胸腺素 β4 及其衍生物则被明确列在 S2.3（生长因子）之下，TB-500 就在其中。",{"q":26,"a":27},"BPC-157 的法律地位是怎样的？","它在美国、欧盟和澳大利亚都不是获批药物；澳大利亚将其列入《毒物标准》附表 4，即凭处方供应。持有和使用是否合法，取决于你所在地的法律。",{"type":29,"children":30,"toc":231},"root",[31,43,48,54,59,64,78,83,88,109,114,120,124,129,133,138,142,147],{"type":32,"tag":33,"props":34,"children":35},"element","disclaimer",{},[36],{"type":32,"tag":37,"props":38,"children":39},"p",{},[40],{"type":41,"value":42},"text","本文仅为一般性信息——不构成医疗建议，不是给药或使用建议，也不是在建议谁去获取或使用任何物质。这两种肽都不是获批药物；在澳大利亚，BPC-157 属于凭处方供应。持有和使用是否合法，取决于你所在国家的法律，责任也在你自己。健康方面的问题，请咨询有执业资格的医生或药师。",{"type":32,"tag":37,"props":44,"children":45},{},[46],{"type":41,"value":47},"这两个名字几乎从不单独出现，久而久之，人们很容易把它们当成同一样东西。下面是一份中立的梳理：各自是什么、研究做到了哪一步、如今处于什么状态。",{"type":32,"tag":49,"props":50,"children":52},"h2",{"id":51},"两者各自是什么",[53],{"type":41,"value":51},{"type":32,"tag":37,"props":55,"children":56},{},[57],{"type":41,"value":58},"BPC-157 是一种人工合成的十五肽，由 15 个氨基酸串成，其序列取自胃液中发现的一段结构。TB-500 则是胸腺素 β4 的人工合成片段——胸腺素 β4 是一种蛋白，文献里常把它与肌动蛋白结合、细胞迁移联系在一起。把两者绑成一对，是网络讨论养出来的习惯，而不是药理学上的分类。",{"type":32,"tag":49,"props":60,"children":62},{"id":61},"研究做到了哪一步",[63],{"type":41,"value":61},{"type":32,"tag":37,"props":65,"children":66},{},[67,69,76],{"type":41,"value":68},"两者的研究几乎全部停在临床前阶段：细胞培养和动物模型。公开的临床试验注册平台上，BPC-157 没有一项已完成的人体疗效对照试验；围绕胸腺素 β4 衍生物登记在案的人体研究也很有限。2026 年，FDA 的审评科学家在梳理证据后报告说，关于 BPC-157，他们基本上只找到一篇小型试验的摘要——受试者约 46 人，而且给药方式并非注射；同一份审评还指出，免疫原性，也就是身体对注射进来的肽产生免疫反应的可能，在这一类物质上大体尚未评估。这份审评的细节，写在我们对 ",{"type":32,"tag":70,"props":71,"children":73},"a",{"href":72},"\u002Fblog\u002Ffda-peptides-503a-vote",[74],{"type":41,"value":75},"503A 那场投票",{"type":41,"value":77},"的解读里。",{"type":32,"tag":49,"props":79,"children":81},{"id":80},"监管地位与反兴奋剂状态",[82],{"type":41,"value":80},{"type":32,"tag":37,"props":84,"children":85},{},[86],{"type":41,"value":87},"在美国、欧盟和澳大利亚，两者都不是获批药物；澳大利亚的《毒物标准》把 BPC-157 列入附表 4，即凭处方供应。在体育领域，两者在任何时候都被禁用，不只是在赛内：BPC-157 归入 S0——世界反兴奋剂机构《禁用清单》中专门收纳「尚无任何人用治疗用途监管批准」之物质的那一类，2026 年版在该类的举例里点了它的名；胸腺素 β4 及其衍生物则被明确写在 S2.3（生长因子）之下，TB-500 就在其中。",{"type":32,"tag":37,"props":89,"children":90},{},[91,93,99,101,107],{"type":41,"value":92},"在美国，FDA 的审评科学家对受审的全部七种肽都给出了否定意见；2026 年 7 月 23 日，药房配制咨询委员会逐个品种投票，建议把 BPC-157 和 TB-500 纳入 503A 条款清单，两次的票型都是 8 票赞成、6 票反对、1 票弃权。所谓 503A 条款清单，是一份原料药清单：一种原料药必须先列入其中，药房才可以用它配制。委员会的投票是一项建议，不是批准。更大的图景：",{"type":32,"tag":70,"props":94,"children":96},{"href":95},"\u002Fpeptides-list",[97],{"type":41,"value":98},"附批准状态的肽类清单",{"type":41,"value":100},"，以及",{"type":32,"tag":70,"props":102,"children":104},{"href":103},"\u002Fare-peptides-legal",[105],{"type":41,"value":106},"肽类合法吗",{"type":41,"value":108},"。",{"type":32,"tag":49,"props":110,"children":112},{"id":111},"常见问题",[113],{"type":41,"value":111},{"type":32,"tag":115,"props":116,"children":118},"h3",{"id":117},"bpc-157-和-tb-500-是什么",[119],{"type":41,"value":20},{"type":32,"tag":37,"props":121,"children":122},{},[123],{"type":41,"value":21},{"type":32,"tag":115,"props":125,"children":127},{"id":126},"bpc-157-和-tb-500-在体育运动中被禁用吗",[128],{"type":41,"value":23},{"type":32,"tag":37,"props":130,"children":131},{},[132],{"type":41,"value":24},{"type":32,"tag":115,"props":134,"children":136},{"id":135},"bpc-157-的法律地位是怎样的",[137],{"type":41,"value":26},{"type":32,"tag":37,"props":139,"children":140},{},[141],{"type":41,"value":27},{"type":32,"tag":49,"props":143,"children":145},{"id":144},"参考来源",[146],{"type":41,"value":144},{"type":32,"tag":148,"props":149,"children":150},"ul",{},[151,167,181,195,208],{"type":32,"tag":152,"props":153,"children":154},"li",{},[155,157,165],{"type":41,"value":156},"WADA，",{"type":32,"tag":70,"props":158,"children":162},{"href":159,"rel":160},"https:\u002F\u002Fwww.wada-ama.org\u002Fen\u002Fprohibited-list",[161],"nofollow",[163],{"type":41,"value":164},"禁用清单",{"type":41,"value":166},"——S0（未获批准的物质）在举例中点名 BPC-157；S2.3（生长因子）列出胸腺素 β4 及其衍生物，例如 TB-500",{"type":32,"tag":152,"props":168,"children":169},{},[170,172,179],{"type":41,"value":171},"TGA，",{"type":32,"tag":70,"props":173,"children":176},{"href":174,"rel":175},"https:\u002F\u002Fwww.tga.gov.au\u002Fproducts\u002Funapproved-therapeutic-goods\u002Fpoisons-standard-susmp",[161],[177],{"type":41,"value":178},"毒物标准（SUSMP）",{"type":41,"value":180},"——BPC-157 列于附表 4",{"type":32,"tag":152,"props":182,"children":183},{},[184,186,193],{"type":41,"value":185},"FDA，",{"type":32,"tag":70,"props":187,"children":190},{"href":188,"rel":189},"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fbulk-drug-substances-used-compounding-under-section-503a-fdc-act",[161],[191],{"type":41,"value":192},"503A 条款下用于配制的原料药",{"type":41,"value":194},"——针对被提名用于配制之原料药的过渡期政策",{"type":32,"tag":152,"props":196,"children":197},{},[198,199,206],{"type":41,"value":185},{"type":32,"tag":70,"props":200,"children":203},{"href":201,"rel":202},"https:\u002F\u002Fwww.fda.gov\u002Fadvisory-committees\u002Fadvisory-committee-calendar\u002Fjuly-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026",[161],[204],{"type":41,"value":205},"药房配制咨询委员会会议，2026 年 7 月 23–24 日",{"type":41,"value":207},"——对 BPC-157、KPV、TB-500 和 MOTS-c 的投票",{"type":32,"tag":152,"props":209,"children":210},{},[211,213,220,222,229],{"type":41,"value":212},"ClinicalTrials.gov，针对 ",{"type":32,"tag":70,"props":214,"children":217},{"href":215,"rel":216},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=BPC-157",[161],[218],{"type":41,"value":219},"BPC-157",{"type":41,"value":221}," 与",{"type":32,"tag":70,"props":223,"children":226},{"href":224,"rel":225},"https:\u002F\u002Fclinicaltrials.gov\u002Fsearch?intr=Thymosin+beta-4",[161],[227],{"type":41,"value":228},"胸腺素 β4",{"type":41,"value":230},"的注册平台检索",{"title":7,"searchDepth":232,"depth":232,"links":233},2,[234,235,236,237,243],{"id":51,"depth":232,"text":51},{"id":61,"depth":232,"text":61},{"id":80,"depth":232,"text":80},{"id":111,"depth":232,"text":111,"children":238},[239,241,242],{"id":117,"depth":240,"text":20},3,{"id":126,"depth":240,"text":23},{"id":135,"depth":240,"text":26},{"id":144,"depth":232,"text":144},"markdown","content:blog:zh:recovery-duo.md","content","blog\u002Fzh\u002Frecovery-duo.md","blog\u002Fzh\u002Frecovery-duo","md"]